|
|
|
Insider
Information: |
Clackson Timothy P |
Relationship: |
|
City: |
Cambridge |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
6 |
|
Direct
Shares |
737,796 |
|
Indirect Shares
|
118,218 |
|
|
Direct
Value |
$359,460 |
|
|
Indirect Value
|
$181,274 |
|
|
Total
Shares |
856,014 |
|
|
Total
Value |
$540,734 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Ariad Pharmaceuticals Inc |
ARIA |
President, R&D, CSO |
2016-03-22 |
316,212 |
2004-01-05 |
0 |
Premium* |
|
F-star Therapeutics, Inc |
FSTX |
Director |
2020-09-30 |
50,486 |
2018-07-02 |
0 |
Premium* |
|
Forma Therapeutics Holdings, Inc., |
FMTX |
Director |
2022-10-14 |
0 |
|
0 |
Premium* |
|
Theseus Pharmaceuticals, Inc. |
THRX |
President and CEO, Dir... |
2022-11-11 |
351,030 |
|
0 |
Premium* |
|
Xilio Therapeutics, Inc. |
XLO |
10% Owner |
2021-10-21 |
20,068 |
2021-10-21 |
70,888 |
Premium* |
|
Elevation Oncology, Inc. |
ELEV |
|
2023-09-01 |
0 |
2023-09-01 |
47,330 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
94 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2016-03-19 |
4 |
AS |
$6.47 |
$35,039 |
D/D |
(5,417) |
340,046 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
Pres., R & D., Chief Sci. Off. |
|
2010-10-26 |
4 |
B |
$3.70 |
$37,000 |
D/D |
10,000 |
117,437 |
2.74 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2015-03-20 |
4 |
AS |
$8.84 |
$47,910 |
D/D |
(5,417) |
433,648 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2012-03-26 |
4 |
OE |
$6.39 |
$47,925 |
D/D |
7,500 |
298,250 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2013-12-19 |
4 |
AS |
$5.14 |
$50,115 |
D/D |
(9,750) |
380,319 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2014-03-21 |
4 |
AS |
$7.89 |
$52,583 |
D/D |
(6,667) |
394,377 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2014-04-02 |
4 |
AS |
$8.21 |
$53,337 |
D/D |
(6,500) |
403,028 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2015-09-28 |
4 |
AS |
$6.46 |
$56,560 |
D/D |
(8,750) |
334,086 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2015-03-23 |
4 |
AS |
$8.55 |
$57,016 |
D/D |
(6,667) |
440,314 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2016-03-03 |
4 |
AS |
$6.12 |
$58,867 |
D/D |
(9,625) |
334,630 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2015-07-16 |
4 |
AS |
$8.54 |
$59,797 |
D/D |
(7,000) |
325,336 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2016-02-01 |
4 |
AS |
$4.81 |
$70,517 |
D/D |
(14,667) |
350,052 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2011-03-22 |
4 |
D |
$6.39 |
$78,424 |
D/D |
(12,273) |
141,373 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2012-04-03 |
4 |
AS |
$16.18 |
$84,134 |
D/D |
(5,200) |
272,489 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2015-02-02 |
4 |
AS |
$6.33 |
$92,820 |
D/D |
(14,667) |
428,232 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2011-04-11 |
4 |
D |
$7.76 |
$103,123 |
D/D |
(13,289) |
180,084 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2012-04-17 |
4 |
AS |
$15.00 |
$106,665 |
D/D |
(7,111) |
233,778 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2013-04-02 |
4 |
S |
$18.04 |
$117,245 |
D/D |
(6,500) |
363,705 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2012-03-26 |
4 |
AS |
$16.00 |
$120,000 |
D/D |
(7,500) |
290,750 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2012-07-30 |
4 |
OE |
$5.23 |
$121,514 |
D/D |
23,234 |
257,403 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2013-03-22 |
4 |
S |
$19.46 |
$129,718 |
D/D |
(6,667) |
338,039 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2012-12-20 |
4 |
OE |
$5.23 |
$141,210 |
D/D |
27,000 |
282,940 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2016-03-02 |
4 |
AS |
$6.00 |
$150,282 |
D/D |
(25,047) |
344,255 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2015-03-19 |
4 |
OE |
$0.00 |
$156,167 |
D/D |
31,490 |
460,971 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
|
2016-03-22 |
4 |
AS |
$6.58 |
$156,871 |
D/D |
(23,834) |
316,212 |
0 |
- |
|
94 Records found
|
|
Page 3 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|